文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

纳吉布肽(TREM-1抑制剂)治疗脓毒性休克的有效性、安全性和最佳生物标志物富集策略的前瞻性评估(ASTONISH):一项双盲、随机、对照2b期试验

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
PubMed 文献 · Lancet Respir Med · 2023-05-31
一句话结论ASTONISH 2b期试验未达主要终点:在预设sTREM-1≥400 pg/mL人群中,纳吉布肽低剂量与高剂量均未显著改善第5天SOFA评分。

ASTONISH为双盲、随机、安慰剂对照2b期试验,在7国42家医院ICU纳入355例脓毒性休克患者,1:1:1随机接受纳吉布肽0.3 mg/kg/h、1.0 mg/kg/h或安慰剂静脉给药。主要终点为基线至第5天SOFA评分变化,在预设sTREM-1≥400 pg/mL人群和总体改良意向治疗人群中评估。高sTREM-1人群中,低剂量组与安慰剂组SOFA评分平均差异0.21(95%CI -1.45至1.87,p=0.80),高剂量组1.39(-0.28至3.06,p=0.104);总体人群中低剂量组0.20(-1.09至1.50,p=0.76),高剂量组1.06(-0.23至2.35,p=0.108)。三组治疗中出现的不良事件和严重不良事件相似。试验未达主要终点;作者认为未来需在更高TREM-1激活浓度患者中确认纳吉布肽的获益。

要点

  • 预设高sTREM-1(≥400 pg/mL)人群中,低剂量组第5天SOFA评分较基线变化与安慰剂组平均差异0.21(95%CI -1.45至1.87,p=0.80),高剂量组1.39(-0.28至3.06,p=0.104),均未达统计学显著。
  • 总体人群中,低剂量组与安慰剂组SOFA评分平均差异0.20(95%CI -1.09至1.50,p=0.76),高剂量组1.06(-0.23至2.35,p=0.108)。
  • 预设高sTREM-1(≥400 pg/mL)人群28天全因死亡率:安慰剂组31%、低剂量组39%、高剂量组28%;总体人群分别为25%、32%、25%。
  • 治疗中出现的不良事件发生率三组相似:安慰剂组96%、低剂量组96%、高剂量组95%;严重治疗中出现的不良事件分别为24%、22%、26%。
  • 基线sTREM-1≥532 pg/mL者,高剂量纳吉布肽较安慰剂在第5天SOFA评分实现≥2分的临床相关改善;低剂量组在所有截断值下呈现类似但幅度更低的效应。

适用人群与场景

  • 非COVID-19、18-85岁、符合脓毒性休克标准定义、有明确或疑似感染(肺部、腹部或尿路[≥65岁患者])的患者,在因脓毒性休克启动血管升压药后24小时内纳入。
  • 来自7个国家42家医院的内科、外科或混合ICU。

诊断标准与关键阈值

  • 脓毒性休克采用标准定义。
  • 基线sTREM-1浓度分组:高sTREM-1定义为≥400 pg/mL(该界值由脓毒症观察性研究和2a期数据变化确定)。
  • 探索性分析界值:sTREM-1≥532 pg/mL。

处置流程与药物剂量

  • 纳吉布肽低剂量:0.3 mg/kg/h,静脉给药。
  • 纳吉布肽高剂量:1.0 mg/kg/h,静脉给药。
  • 安慰剂:匹配安慰剂,静脉给药。
  • 随机分组比例1:1:1,采用计算机生成的区组随机方案(区组大小3)。

研究设计与关键结果

  • 研究类型:双盲、随机、安慰剂对照2b期试验;7国42家医院;2019年11月14日至2022年4月11日筛查402例,355例纳入主要分析(安慰剂组116例、低剂量组118例、高剂量组121例)。
  • 初步高sTREM-1人群共253例(占355例的71%):安慰剂组75例(占116例的65%)、低剂量组90例(占118例的76%)、高剂量组88例(占121例的73%)。
  • 主要终点(高sTREM-1≥400 pg/mL人群第5天SOFA评分较基线平均差异):低剂量组vs安慰剂组0.21(95%CI -1.45至1.87,p=0.80);高剂量组vs安慰剂组1.39(-0.28至3.06,p=0.104)。
  • 总体人群第5天SOFA评分较基线平均差异:低剂量组vs安慰剂组0.20(95%CI -1.09至1.50,p=0.76);高剂量组vs安慰剂组1.06(-0.23至2.35,p=0.108)。
  • 预设高sTREM-1(≥400 pg/mL)人群28天全因死亡率:安慰剂组23/75(31%)、低剂量组35/90(39%)、高剂量组25/88(28%)。
  • 总体人群28天全因死亡率:安慰剂组29/116(25%)、低剂量组38/118(32%)、高剂量组30/121(25%)。
  • 治疗中出现的不良事件:安慰剂组111/116(96%)、低剂量组113/118(96%)、高剂量组115/121(95%);严重治疗中出现的不良事件:安慰剂组28例(24%)、低剂量组26例(22%)、高剂量组31例(26%)。
  • 基线sTREM-1≥532 pg/mL者,高剂量纳吉布肽较安慰剂在第5天SOFA评分实现≥2分的临床相关改善;低剂量组在所有截断值下呈现类似但幅度更低的效应。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照2b期试验。
  • 主要终点未达到:在预设sTREM-1界值下未改善SOFA评分。
  • 局限:作者指出未来研究需在更高TREM-1激活浓度患者中确认纳吉布肽的获益。

对床旁实践的改变

  • 作者认为,未来需在更高TREM-1激活浓度患者中进一步研究以确认纳吉布肽的获益。
  • 该试验在预设sTREM-1≥400 pg/mL人群中未达到主要终点,纳吉布肽0.3 mg/kg/h和1.0 mg/kg/h静脉给药未显著改善第5天SOFA评分。

指南或共识出处

  • ASTONISH试验,EudraCT 2018-004827-36,ClinicalTrials.gov NCT04055909。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Activation of the triggering receptor expressed on myeloid cells-1 (TREM-1) pathway is associated with septic shock outcomes. Data suggest that modulation of this pathway in patients with activated TREM-1 might improve survival. Soluble TREM-1 (sTREM-1), a potential mechanism-based biomarker, might facilitate enrichment of patient selection in clinical trials of nangibotide, a TREM-1 modulator. In this phase 2b trial, we aimed to confirm the hypothesis that TREM1 inhibition might improve outcomes in patients with septic shock.

METHODS: This double-blind, randomised, placebo-controlled, phase 2b trial assessed the efficacy and safety of two different doses of nangibotide compared with placebo, and aimed to identify the optimum treatment population, in patients across 42 hospitals with medical, surgical, or mixed intensive care units (ICUs) in seven countries. Non-COVID-19 patients (18-85 years) meeting the standard definition of septic shock, with documented or suspected infection (lung, abdominal, or urinary [in patients ≥65 years]), were eligible within 24 h of vasopressor initiation for the treatment of septic shock. Patients were randomly assigned in a 1:1:1 ratio to intravenous nangibotide 0·3 mg/kg per h (low-dose group), nangibotide 1·0 mg/kg per h (high-dose group), or matched placebo, using a computer-generated block randomisation scheme (block size 3). Patients and investigators were masked to treatment allocation. Patients were grouped according to sTREM-1 concentrations at baseline (established from sepsis observational studies and from phase 2a change to data) into high sTREM-1 (≥ 400 pg/mL). The primary outcome was the mean difference in total Sequential Organ Failure Assessment (SOFA) score from baseline to day 5 in the low-dose and high-dose groups compared with placebo, measured in the predefined high sTREM-1 (≥ 400 pg/mL) population and in the overall modified intention-to-treat population. Secondary endpoints included all-cause 28-day mortality, safety, pharmacokinetics, and evaluation of the relationship between TREM-1 activation and treatment response. This study is registered with EudraCT, 2018-004827-36, and Clinicaltrials.gov, NCT04055909.

FINDINGS: Between Nov 14, 2019, and April 11, 2022, of 402 patients screened, 355 were included in the main analysis (116 in the placebo group, 118 in the low-dose group, and 121 in the high-dose group). In the preliminary high sTREM-1 population (total 253 [71%] of 355; placebo 75 [65%] of 116; low-dose 90 [76%] of 118; high-dose 88 [73%] of 121), the mean difference in SOFA score from baseline to day 5 was 0·21 (95% CI -1·45 to 1·87, p=0·80) in the low-dose group and 1·39 (-0·28 to 3·06, p=0·104) in the high-dose group versus placebo. In the overall population, the difference in SOFA score from baseline to day 5 between the placebo group and low-dose group was 0·20 (-1·09 to 1·50; p=0·76),and between the placebo group and the high-dose group was 1·06 (-0·23 to 2·35, p=0·108). In the predefined high sTREM-1 cutoff population, 23 (31%) patients in the placebo group, 35 (39%) in the low-dose group, and 25 (28%) in the high-dose group had died by day 28. In the overall population, 29 (25%) patients in the placebo, 38 (32%) in the low-dose, and 30 (25%) in the high-dose group had died by day 28. The number of treatment-emergent adverse events (111 [96%] patients in the placebo group, 113 [96%] in the low-dose group, and 115 [95%] in the high-dose group) and serious treatment-emergent adverse events (28 [24%], 26 [22%], and 31 [26%]) was similar between all three groups. High-dose nangibotide led to a clinically relevant improvement in SOFA score (of two points or more) from baseline to day 5 over placebo in those with higher cutoff concentrations (≥532 pg/mL) of sTREM-1 at baseline. Low dose nangibotide displayed a similar pattern with lower magnitude of effect across all cutoff values.

INTERPRETATION: This trial did not achieve the primary outcome of improvement in SOFA score at the predefined sTREM-1 value. Future studies are needed to confirm the benefit of nangibotide at higher concentrations of TREM-1 activation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. François B, Lambden S, Fivez T, et al. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023. PMID: 37269870. doi:10.1016/S2213-2600(23)00158-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。